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Abstract
Infections by multidrug-resistant (MDR) bacteria are a worrisome phenomenon in hematological patients. Data on the
incidence of MDR colonization and related bloodstream infections (BSIs) in haematological patients are scarce. A
multicentric prospective observational study was planned in 18 haematological institutions during a 6-month period. All
patients showingMDR rectal colonization as well as occurrence of BSI at admission were recorded. One-hundred forty-four
patients with MDR colonization were observed (6.5% of 2226 admissions). Extended spectrum beta-lactamase (ESBL)-
producing (ESBL-P) enterobacteria were observed in 64/144 patients, carbapenem-resistant (CR) Gram-negative bacteria
in 85/144 and vancomycin-resistant enterococci (VREs) in 9/144. Overall, 37 MDR-colonized patients (25.7%) developed
at least one BSI; 23 of them (62.2%, 16% of the whole series) developed BSI by the same pathogen (MDRrel BSI), with a
rate of 15.6% (10/64) for ESBL-P enterobacteria, 14.1% (12/85) for CR Gram-negative bacteria and 11.1% (1/9) for VRE.
In 20/23 cases, MDRrel BSI occurred during neutropenia. After a median follow-up of 80 days, 18 patients died (12.5%).
The 3-month overall survival was significantly lower for patients colonized with CR Gram-negative bacteria (83.6%) and
VRE (77.8%) in comparison with those colonized with ESBL-P enterobacteria (96.8%). CR-rel BSI and the presence of a
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urinary catheter were independent predictors of mortality. MDR rectal colonization occurs in 6.5% of haematological
inpatients and predicts a 16% probability of MDRrel BSI, particularly during neutropenia, as well as a higher probability
of unfavourable outcomes in CR-rel BSIs. Tailored empiric antibiotic treatment should be decided on the basis of
colonization.
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Introduction
Multidrug-resistant (MDR) bacteria, particularly Gram-
negative (Gram-neg) strains, are a growing and worrisome
phenomenon worldwide, with a demonstrated increase in
mortality and public health costs [1]. As only few antibi-
otics at present are active against MDR bacteria, prevention
is still considered the best strategy. This includes epidemi-
ologic surveillance of colonization and infection and
prompt isolation of cases. Identifying bacterial colonization
may allow to better select empiric antibiotic treatment at the
onset of fever or infection, and early adequate therapy ob-
tains a better response in MDR infections [2, 3]. Gut decon-
tamination is also a potential tool for preventing
carbapenem-resistant (CR) enterobacteria infections, but
its efficacy is often limited, and it may induce antibiotic
resistance [4].
Haematological cancer patients are considered a population
at risk for MDR infections because they experience prolonged
antibiotic pressure and hospitalizations [5, 6]. Recently, in a
retrospective Italian study, the incidence of CR Klebsiella
pneumoniae infection was 0.4 and 2% in autologous and al-
logeneic stem cell transplantation (SCT), respectively.
Infection-related mortality was 16% in autologous and
64.4% in allogeneic SCT [7]. Mortality caused by CR
K. pneumoniae and MDR Pseudomonas aeruginosa was also
unacceptably high among haematological cancer patients,
ranging between 36 and 58% [8, 9]. Vancomycin-resistant
enterococci (VREs) were associated with reduced survival in
SCT recipients, although the attributable mortality was rela-
tively low [10].
Available data concerning the real-life epidemiology of
MDR bacterial strains among haematological patients are
scarce, as are studies on the relationship between rectal colo-
nization and infection, particularly the risk of bloodstream
infections (BSIs), which has been analysed so far in few ret-
rospective and prospective studies [11, 12].
Therefore, a multicentric prospective observational
study was conducted in the haematological setting within
the SEIFEM (Sorveglianza Epidemiologica Infezioni
Fungine in Emopatie Maligne) group to clarify the inci-
dence of MDR bacterial colonization, the probability of
developing MDR BSI in colonized patients and their
outcomes.
Patients and methods
Design of the study
This prospective observational study was conducted by
18 haematological institutions participating in the
SEIFEM. The study was approved by the ethics commit-
tee of each of the participating institutions, and informed
consent was obtained from all patients for being included
in the study. The procedures followed were in accordance
with the ethical standards of the responsible committee
on human experimentation (institutional and national)
and with the Helsinki Declaration of 1975, as revised in
2000.
During a 6-month period, betweenMarch 1 and August 31,
2015, all patients with a haematological neoplasm admitted to
18 Italian centres participating in SEIFEM were screened at
admission for MDR colonization with a rectal swab. Each
hospital conducted screening rectal swab according to its
own protocols. Rectal swabs were streaked onto selective
agar; species identification was made, and antimicrobial sus-
ceptibility was tested by disk diffusion method. Both Gram-
neg and Gram-positive (Gram-pos) MDR colonizing bacteria
were considered in the final analysis. Patients showing rectal
MDR bacterial colonization were recorded in a database
where the occurrence of any BSI was correlated with age,
sex, type and phase of disease, stem cell transplantation, pre-
vious antibiotic treatment, presence of invasive devices, and
type of colonizing bacteria. The follow-up was conducted for
at least 1 month (range 30–270 days) after the date of known
colonization.
Definitions
BSI was defined by the isolation of a bacterium in one blood
culture; two positive cultures were required for diagnosing
coagulase-negative staphylococci or Corynebacterium spp.
BSI.
Antimicrobial resistance was defined according to the
EUCAST clinical breakpoint [13]. Vancomycin resistance
was considered with an MIC of > 4 mg/L for Enterococcus
spp. and carbapenem resistance with an MIC of > 8 for
imipenem for Pseudomonas spp., Acinetobacter spp. and
Enterobacteriaceae. Extended spectrum beta-lactamase
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(ESBL) screening in Enterobacteriaceae was determined by
the broth microdilution method (ESBL production if a ≥ 8-
fold reduction is observed in theMIC of a cephalosporin, such
as cefotaxime, ceftazidime or cefepime, combined with
clavulanic acid than the MIC of cephalosporin alone) or by
the combination disk method (cephalosporin alone and in
combination with clavulanic acid; ESBL production if the
inhibition zone diameter is ≥ 5 mm larger with clavulanic acid
than without).
Bacteria showing resistance to at least one agent in three
or more antimicrobial categories were defined as MDR
[14].
Statistical analysis
Standard descriptive statistics, such as medians, ranges and
proportions, were used to summarize the data. The χ2 test
was used to compare differences in the percentage in a uni-
variate analysis. Variables found to be significant (p < 0.1) in
the univariate analysis were tested in a multivariate analysis,
which was performed using a stepwise logistic regression
model. Values of p < 0.05 were considered statistically signif-
icant. Patient characteristics, type and phase of disease, pres-
ence of invasive devices and previous antibiotic treatment
were analysed in relation to each type of MR colonization.
Table 1 Characteristics of MDR
colonized 144 patients Characteristics Total (n = 144)
Male/female ratio 92/52
Median age, years (range) 60 (0–89)
Paediatric age (< 18, %) 7 (4.9%)
Age ≥ 60 years (%) 75 (52%)
Underlying haematological disease
Acute leukaemia (%) 60 (41.7%)
Myeloid 46
Lymphoblastic 14
Lymphoma (%) 60 (41.7%)
Non-Hodgkin lymphoma 51
Hodgkin lymphoma 6
Chronic lymphocytic leukaemia 3
Myeloma (%) 17 (11.8%)
Myelodysplastic/myeloproliferative disease (%) 5 (3.4%)
Aplastic anaemia (%) 2 (1.4%)
Phase of haematological disease
Disease onset/induction chemotherapy (%) 37 (25.7%)
Complete or partial remission/consolidation chemotherapy (%) 68 (47.2%)
Relapsed or refractory disease/reinduction chemotherapy (%) 39 (27.1%)
Previous antibiotic treatment
Fluoroquinolone prophylaxis (%) 74 (48.6%)
Cephalosporin treatment (%) 59 (41%)
Carbapenem treatment (%) 49 (34%)
Presence of invasive devices
Central venous catheter (%) 83 (57.6%)
Urinary catheter (%) 25 (13.9%)
Autologous stem cell transplantation (%) 25 (17.4%)
Lymphoma (%) 15 (60%)
Myeloma (%) 10 (40%)
Allogeneic stem cell transplantation (%) 15 (10.4%)
Acute myeloblastic leukaemia (%) 8 (53.3%)
Acute lymphoblastic leukaemia (%) 2 (13.3%)
Myeloma (%) 2 (13.3%)
Myelodysplastic/myeloproliferative disease (%) 2 (13.3%)
Severe aplastic anaemia (%) 1 (6.7%)
The chatacters in italic refers to subtype of disease
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The above-mentioned variables, together with types of MDR
colonization, stem cell transplantation and intensive care unit
admission, were included in the analysis of all MR-related
BSIs, ESBL-P-related BSIs, CR-related BSIs and VRE-
related BSIs. In the 30-day mortality analysis, all types of
MR-related BSIs were also considered. Overall survival
(OS) rates were estimated according to the method of
Kaplan and Meier, and comparison between the groups was
done with log-rank test.
Results
Epidemiology of colonization
During the 6-month study period, 144 patients withMDR rectal
colonization were observed. VREs were responsible for colo-
nization in 9/144 (6.3%) of ESBL-producing (ESBL-P)
Enterobacteriaceae in 64/144 (44.4%) and CR Gram-neg bac-
teria in 85/144 (59%) patients, respectively. Fourteen patients
showed both ESBL-P and CR Enterobacteriaceae
colonizations.
The incidence of MDR rectal colonization was 6.5% of all
admissions (144/2226), with a predominance of CR and
ESBL-P bacteria in comparison with VRE (respectively: 85/
2226, 3.8% and 64/2226, 2.9% vs 9/2226, 0.4% of the entire
cohort). The characteristics of MDR-colonized patients are
summarized in Table 1.
We also evaluated the incidence according to diagnosis and
phase of haematological disease (Table 2). Overall, the inci-
dence of MDR colonization appeared to be lower at disease
onset or during induction therapy.
Incidence of BSI in MDR-colonized patients
Overall, 37/144 patients (25.7%) colonized with MDR bacte-
ria developed at least one BSI during the period of observation;
23/37 (62.2%, corresponding to 16% [23/144] of the whole
series) developed BSIs by the same pathogen (MDRrel BSI) (1
VRE, 9 ESBL-P Escherichia coli, 1 ESBL-P K. pneumoniae,
8 CR K. pneumoniae, 1 CR Enterobacter aerogenes, 1 CR
P. aeruginosa and 2 CR Acinetobacter spp.). The median time
from MDR colonization to MDRrel BSI was 12 days (range
0–74). In 87% of the cases, MDRrel BSI occurred during
neutropenia (20/23).
The rate of MDRrel BSI according to the type of antibiotic
resistance was 11.1% (1/9) for VRE colonization, 15.6% (10/
64) for ESBL-P Enterobacteriaceae and 14.1% (12/85) for CR
Gram-neg bacteria. Among CR-colonizing Enterobacteriaceae,
only K. pneumoniae and Enterobacter spp. were associated
with MDRrel BSI (8/37, 21.6% and 1/5, 20%, respectively)
(Table 3).
Table 2 Incidence of different
type of MDR bacteria
colonization according to
diagnosis and phase of
haematological disease
VRE
(%)
ESBL-P Enterobacteriaceae
(%)
CarbaR Gram-negative bacteria
(%)
AML (n)
Induction chemotherapy (292) 0 (–) 3 (1) 8 (2.7)
Consolidation chemotherapy
(303)
4 (1.3) 7 (2.3) 11 (3.6)
Salvage chemotherapy (172) 0 (–) 3 (1.7) 10 (5.8)
ALL (n)
Induction chemotherapy (65) 0 (–) 1 (1.5) 1 (1.5)
Consolidation chemotherapy
(111)
0 (–) 5 (4.5) 5 (4.5)
Salvage chemotherapy (49) 0 (–) 0 (–) 2 (4.1)
Lymphoma (n)
Disease onset (365) 2 (0.5) 7 (1.9) 9 (2.5)
Complete/partial remission
(339)
2 (0.6) 14 (4.1) 12 (3.5)
Relapse/refractory disease
(218)
1 (0.5) 10 (4.6) 11 (5)
Myeloma (n)
Disease onset (20) 0 (–) 1 (5) 1 (5)
Complete/partial remission
(176)
0 (–) 9 (5.1) 4 (2.3)
Relapse/refractory disease (60) 0 (–) 1 (1.7) 3 (5)
VRE vancomycin-resistant enterococci, ESBL-P extended spectrum beta lactamases producers, CarbaR carba-
penem resistant, AML acute myeloid leukaemia, ALL acute lymphoblastic leukaemia.
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Unrelated BSIs were observed in 17/144 colonized patients
(11.8% of the whole series, corresponding to 45.9% of all
patients developing a BSI), including 3 de-novo MDR BSIs
(1 CR P. aeruginosa and 1 CR K. pneumoniae and 1 VRE,
which have occurred respectively 19, 31 and 8 days after
screening admission) (Table 3). In 2/85 (2.4%) patients with
CR-Gram-neg colonization (CR K. pneumoniae and CR
P. aeruginosa), a concomitant candidaemia was observed.
Predictive factors for colonization and MDRrel BSI
Among MDR-colonizing bacteria, a correlation with previous
antibiotic exposure was observed only for VRE colonization,
associated with cephalosporin treatment (p = 0.02, chi-square
test). A multivariate model to analyse the risk of VRE coloni-
zation could not be established due to the small sample size.
Multivariate analysis was performed to analyse the risk of
ESBL-P enterobacteria and CR Gram-neg colonization. No
association with previous antibiotic exposure was found for
ESBL-P and CR colonization. ESBL-P colonization was less
frequent in patients with urinary catheters (OR 0.2, CI 0.08–
0.7) and with acute leukaemia (OR 0.4, CI 0.2–0.8). Younger
(< 60 years) patients (OR 2.1, CI 1–4.2, p = 0.04) not under-
going autologous SCT (OR 2.7, CI 1.1–6.8) and with urinary
catheter showed more frequent colonization by CR Gram-neg
bacteria (OR 3, CI 1–8.8, p = 0.002).
Multivariate analysis of predictor variables for develop-
ing MDRrel BSI revealed that having lymphoma or a
responding haematological disease was protective (OR 0.2,
CI 0.06–0.6, p = 0.007 and OR 0.3, CI 0.1–0.9, p = 0.03,
respectively). Table 4 summarizes the statistical analyses
for MDRrel BSI.
Statistical analyses of predictor variables for the MDRrel
BSI subtype was performed only for ESBL-P and CR rel BSI.
ESBL-P colonization was strictly related to ESBL-P-rel BSI
(OR 26, CI 3–207, p = 0.002); CR-rel BSI was correlated with
Table 3 MDRrel and unrelated
BSI according to type of
colonising MDR bacteria
Type of colonising MDR bacteria (N) MDRrel BSI (%) Unrelated BSI (%) (type)
VRE (9) 1 (11.1%) 1 (11.1%)
1 P. aeruginosa
ESBL-P E. coli (50) 9 (18%) 2 (4%)
1 S. hominis
1 S. epidermidis
ESBL-P K. pneumoniae (6) 1 (16.7%) 0 (–)
ESBL-P Enterobacter spp. (5) 4 (80%) 0 (–)
CarbaR C. freundii (3) 0 (−) 0 (–)
CarbaR Enterobacter spp. (5) 1 (20%) 0 (–)
CarbaR E. coli (20) 0 (−) 3 (15%)
1 E. faecalis
1 S. epidermidis
1 P. aeruginosa
CarbaR K. pneumoniae (37) 8 (21.6%) 7 (18.9%)
1 S. haemolyticus
1 Vancomycin-resistant E. faecalis
2 P. aeruginosa
1 MDR P. aeruginosa
1 K. pneumoniaea
1 R. mucilaginosa + C. albicans
CarbaR M. morganii (2) 0 (−) 0 (–)
CarbaR P. mirabilis (3) 0 (−) 1 (33%)
1 S. aureus
MDR Acinetobacter spp. (9) 2 (22.2%) 1 (11.1%)
1 S. haemolyticus + C. albicans
MDR P. aeruginosa (10) 1 (10%) 2 (20%)
1 S. epidermidis
1 CR K. pneumoniae
MDR multidrug resistant, CarbaR carbapenem resistant
a Not carbapenem resistant
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relapsed/refractory haematological disease (OR 14.2, CI 2.7–
74.7, p = 0.002) and with the presence of a urinary catheter
(OR 14.5, CI 2.4–87.9, p = 0.004), whereas a diagnosis of
lymphoma was protective for CR-rel BSI (OR 0.3, CI
0.002–0.4, p = 0.007).
Outcome of MDR colonized patients
After a median follow-up of 80 days (range 30–270), 18/144
patients died (12.5%). Survival data collected at day 80 were
available for all the 144 patients. The 3-month OS of the entire
cohort was 88.36% ± 2.99 SE, being significantly lower in
patients colonized with VRE (77.78% ± 13.86 SE) and CR
Gram-neg (83.57% ± 4.79 SE) in comparison with those col-
onized with ESBL-P enterobacteria (96.8% ± 2.23 SE, p =
0.033 and 0.02, respectively) (Fig. 1a, b).
The 30-day mortality from MDR colonization was 10/144
(6.9%) and was attributable to MDRrel BSI in 6/10 patients
(60%), specifically to CR-rel BSIs in 5 patients (3 CR
K. pneumoniae, 1 CR P. aeruginosa and 1 CR Acinetobacter
spp.) and to VRE-rel BSI in 1 patient. One de-novo CR
P. aeruginosa BSI was fatal within 30 days.
Table 4 Univariate and
multivariate analyses for MDRrel
BSI
Univariate analysis
%, p
Multivariate analysis
OR (95% CI), p
Diagnosis
- Acute leukaemia (Y vs N) 52 vs 40, 0.26 –
- Lymphoma (Y vs N) 17 vs 45, 0.01 0.2 (0.06–0.6), 0.007
- Myeloma (Y vs N) 22 vs 10, 0.11 –
Age
- ≥ 60 (Yvs N) 57 vs 50, 0.59 –
Sex
- Male (Y vs N) 57 vs 67, 0.34 –
- Female 43 vs 33, 0.34 –
Disease onset/induction phase
- Y vs N 26 vs 26, 0.96 –
Complete/partial remission
- Y vs N 30 vs 50, 0.08 0.3 (0.1–0.9), 0.03
Relapsed/refractory disease
- Y vs N 43 vs 25, 0.07 –
Previous Fq prophylaxis
- Y vs N 61 vs 49, 0.32 –
Previous cephalosporin tx
- Y vs N 40 vs 41, 0.95 –
Previous carbapenem tx
- Y vs N 26 vs 44, 0.11 –
CVC
- Yvs N 61 vs 58, 0.79 –
Urinary catheter
- Y vs N 22 vs 17, 0.54 –
Previous intensive care admission
- Y vs N 9 vs 6, 0.60 –
Type of MDR colonization
- VRE (Y vs N) 4 vs 7, 0.68 –
- ESBL-P enterobacteria (Y vs N) 43 vs 45, 0.68 –
- CR Gram-neg (Y vs N) 57 vs 60, 0.79 –
SCT
- Autologous (Y vs N) 26 vs 16, 0.25 –
- Allogeneic (Y vs N) 9 vs 11, 0.77 –
The chatacters in italic refers to subtype of disease
Fq fluoroquinolone, Tx therapy, CVC central venous catheter
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CR-rel BSI (OR 17.5, CI 3.5–86.4, p = 0.0004) and the
presence of a urinary catheter (OR 3.9, CI 1–17.2, p = 0.04)
were independent predictors of mortality at 30 days from
MDR colonization, as revealed by the multivariate analysis
(Table 5).
Discussion
In this large multicentre Italian survey, the incidence of MDR
rectal colonization documented at admission and the probabil-
ity of developing a related BSI was evaluated among all ad-
mitted patients with haematologic malignancies.
The overall incidence of MDR-colonized patients was 6.5%,
with a predominance of CR and ESBL-P bacteria in comparison
with VRE, particularly during consolidation or salvage treat-
ment. Incidence distribution showed a certain variability, rang-
ing from 0 to 21% depending on the centre. The VRE and
ESBL-P colonization frequency were lower in comparison with
data reported by Liss et al. [15], which showed an incidence of
9.9 and 17.5%, respectively. This discrepancy may be due to the
different populations studied and to the different screening
methods used. The German study included both oncological
and haematological patients, and colonization was also
evaluated in stool samples. Indeed, in a subsequent multicentre
German study evaluating both rectal swabs and stool samples
and performed in high risk haematologic patients, the incidence
of ESBL-P enterobacteria colonization was 11.1% [12], but it
was sharply lower (1.33–3.21%) in a study considering only
rectal swabs [16]. In a recent meta-analysis [17], showing an
overall rate of colonization of 19%, data reported from single
studies analysed were highly variable depending from the dif-
ferent populations analysed and from their geographic origin, as
well as from the screening methods used.
The rate of colonization byCRK. pneumoniaewas 2.6% in
our study, slightly higher than that reported by Girmenia et al.
in SCT [7], confirming that this is a growing problem in en-
demic areas, such as Italy.
The predictive factors for MDR colonization are difficult to
identify, and our study is not primarily designed to this end. In
particular, the impact of previous antibiotic prophylaxis or
other antibiotic treatment could not be evaluated, as data on
non-colonized patients were not available. However, consid-
ering CR Gram-neg colonization, commonly regarded as a
marker of illness severity, it was more frequent in patients of
younger age, carrying a urinary catheter and undergoing treat-
ments different from autologous SCT.
In our study, MDRrel BSIs were observed in 16% of colo-
nized patients, representing approximately two thirds of all
BSIs observed in this setting of patients. The probability of
MDRrel BSI was similar for different types of MDR bacteria,
confirming the propensity to develop a BSI, regardless of the
type of colonizing bacteria. Unrelated BSIs occurred in 11.8%
of MDR-colonized patients, with both Gram-pos and Gram-
neg bacterial BSIs. Notably, the only two cases of candidaemia
occurred in CR Gram-neg bacteria colonized patients.
The rate of VRE- and ESBL-P-BSIs in colonized patients
reported is variable. In our study, it was similar to those re-
ported by Zaas and Cornejo-Juárez [18, 19] but much higher
than in other studies [12, 15]. Notably, only K. pneumoniae
and E. aerogenes, among CR enterobacteria, were responsible
for MDRrel BSIs. This finding may be explained by a higher
virulence of Klebsiella and Enterobacter genera in compari-
son with other enterobacteria. The rate of MDRrel BSIs in CR
K. pneumoniae-colonized patients (21.6%) was comparable in
our study with the approximately 30% incidence reported by
Girmenia et al. [7], considering the type of population in our
study, which includes only 15 allogeneic SCT patients. These
data confirm the importance of a tailored empiric antibiotic
treatment in MDR colonized febrile patients, particularly dur-
ing neutropenia. On the other hand, non-colonized patients,
under conditions of clinical stability, should not receive em-
pirically ESBL- or CR-active agents.
Data concerning the predictive factors of MDRrel BSIs
among haematologic patients are scant. Our study showed that
both a diagnosis of lymphoma and a controlled haematologi-
cal disease were protective. Therefore, these groups of MDR-
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Fig. 1 Overall survival of 144 colonized patients (a) and according to
type of colonization (b)
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Table 5 Univariate and
multivariate analysis for 30-day
mortality from known MDR
colonization
Univariate analysis
%, p
Multivariate analysis
OR (95% CI), p
Diagnosis
- Acute leukaemia (Y vs N) 30 vs 43, 0.44 –
- Lymphoma (Y vs N) 50 vs 40, 0.55 –
- Myeloma (Y vs N) 10 vs 12, 0.85 –
Age
- ≥ 60 (Yvs N) 70 vs 50, 0.22 –
Sex
- Male (Y vs N) 60 vs 66, 0.72 –
- Female 40 vs 34, 0.72 –
Disease onset/induction phase
- Y vs N 50 vs 24, 0.07 –
Complete/partial remission
- Y vs N 10 vs 50, 0.01 –
Relapsed/refractory disease
- Y vs N 40 vs 27, 0.37 –
Previous Fq prophylaxis
- Y vs N 60 vs 51, 0.57 –
Previous cephalosporin tx
- Y vs N 40 vs 41, 0.95 –
Previous carbapenem tx
- Y vs N 50 vs 33, 0.27 –
CVC
- Yvs N 40 vs 60, 0.22 –
Urinary catheter
- Y vs N 50 vs 15, 0.005 3.9 (1–17.2)
Type of MDR colonization
- VRE (Y vs N) 20 vs 5, 0.08 –
- ESBL-P enterobacteria (Y vs N) 10 vs 47, 0.02 –
- CR Gram-neg (Y vs N) 80 vs 57, 0.16 –
SCT
- Autologous (Y vs N) 0 vs 15, 0.13 –
- Allogeneic (Y vs N) 10 vs 10, 0.96 –
MDR-rel BSI
- Y vs N 60 vs 13, <0.0001 –
VRE-rel BSI
- Y vs N 10 vs 0, 0.0002 –
ESBL-P enterobacteria BSI
- Y vs N 0 vs 8, 0.37 –
CR-rel Gram-neg BSI
- Y vs N 50 vs 5, <0.0001 17.5 (3.5–86.4), 0.0004
Unrelated BSI
- Y vs N 10 vs 12, 0.85 –
Unrelated MDR BSI
- Y vs N 0 vs 2, 0.63 –
The chatacters in italic refers to subtype of disease
Fq fluoroquinolone, Tx therapy, CVC central venous catheter
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colonized patients may be considered at low risk of develop-
ing MDR-rel BSIs.
The 3-month OS was lower in patients colonized with CR
Gram-neg bacteria or VREs than ESBL-P enterobacteria.
None of the patients with ESBL-P-rel BSI died, and the
30-day mortality was lower in ESBL-P colonized patients
(10 vs 47%, 0.02 at the univariate analysis). This observa-
tion, together with an association of ESBL-P colonization
with a diagnosis different from AL and with the absence of
a urinary catheter, may prompt a re-evaluation of the clinical
impact of ESBL-P Enterobacteriaceae in haematologic
patients.
The MDRrel BSI-attributable 30-day mortality in CR and
VRE was high (60%), mainly due to CR-rel BSIs. The devel-
opment of MDRrel BSI was the only predictive factor for
death in colonized patients as revealed by multivariate analy-
sis, together with the presence of a urinary catheter,
confirming the severity of this condition, as was also reported
in other series [20, 21].
In conclusion, our multicentric study showed a relatively
low incidence of MDR rectal colonization in haematological
cancer patients. However, this condition predicts a probability
of 16% of MDRrel BSI, particularly during neutropenic
phases, and a higher percentage of unfavourable outcomes
in case of CR-rel BSIs. Among CR enterobacteria, only
Klebsiella and Enterobacter genera appear to have a propen-
sity to develop related BSIs. CR Gram-neg colonization con-
figures a poor prognostic setting in comparison with ESBL-P
enterobacteria colonization, which appears to be a less severe
condition in haematologic cancer patients. Taken together,
these data confirm that the choice of empiric antibiotic treat-
ment should be guided by known colonization in haematologic
patients.
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